A Study to Evaluate the Effect of IV Doses of Rivipansel on Subjects With Renal Impairment and in Healthy Subjects

• Status: Completed
• Trial end date: 2018-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the effect of renal impairment on rivipansel.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: GlycoMimetics Incorporated; Pfizer

Criteria

Inclusion Criteria:

• Female subjects of non-childbearing potential or male subjects

• Body Mass Index (BMI) of 17.5 to 40.0 kg/m2

• Stable renal function

Exclusion Criteria:

• A positive urine drug screen for illicit drugs

• Treatment with an investigational drug within 30 days of the dose of study medication

• Pregnant females, breastfeeding female subjects and male subjects with partners currently pregnant

• Use of herbal supplements in the 28 days prior to the dose of study medication

• Blood donation (excluding plasma donation) of approximately 1 pint or more within 56 days prior to study medication

• Requiring dialysis